Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Nat Rev Cancer. 2015 Jan;15(1):7–24. doi: 10.1038/nrc3860

Table 3. Dual pan-PI3K and mTOR inhibitors and their clinical applications.

Agent Company Target Trial stage* Tumor types*
GDC0980 Genentech PI3K and mTOR I and II

  • Prostate

  • Breast

  • Endometrial

  • Renal cell

  • Non-Hodgkin lymphoma

  • Adv. solid tumors
PF04691502 Pfizer PI3K and mTOR I

  • Adv. solid tumors
BGT226 Novartis PI3K and mTOR I and II

  • Adv. solid tumors
BEZ235 Novartis PI3K and mTOR I and II

  • Breast

  • Renal cell

  • Prostate

  • TCC

  • ALL

  • AML

  • CML

  • Pancreatic neuroendocrine

  • Adv. solid tumors
XL765 Sanofi PI3K and mTOR I

  • GBM

  • Adv. solid tumors
GSK2126458 GlaxoSmithKline PI3K and mTOR I

  • Solid tumors

  • Lymphoma
DS7423 Daiichi Sankyo PI3K and mTOR I Solid tumors
PWT33597 Pathway Therapeutics PI3K and mTOR I Adv. solid tumors
SF1126 Semafore Pharmaceuticals PI3K and mTOR I Adv. solid tumors
PF05212384 Pfizer PI3K and mTOR I and II Adv. solid tumors
*

Data taken from an April 2014 search of http://www.clinicaltrials.gov.

TCC, transitional cell carcinoma; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myelogenous leukemia; GBM, glioblastoma multiforme